August 06, 2026

National Stock Exchange of India Limited,
Compliance Department,
Exchange Plaza, Bandra Kurla Complex,
Bandra (East), Mumbai - 400051,
Maharashtra, India

BSE Limited,
Compliance Department,
Phiroze Jeejeebhoy Towers,
Dalal Street, Mumbai - 400001,
Maharashtra, India

Dear Sir/Madam,

Subject : ***Intimation regarding investment in HCG Rajkot Hospitals LLP, Wholly Owned Subsidiary by HealthCare Global Enterprises Limited (the Company")***

Stock Code : ***BSE – 539787, NSE – HCG***

Reference : ***Regulation 30(2) and (6) read with Schedule III Part A Para A sub-para (1) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("LODR Regulations") read with SEBI Master Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 issued on July 11, 2023, and last updated on January 30, 2026 ("SEBI Circular")***

This is to inform you that, the Board of Directors of the Company has, at their meeting held on August 06, 2026, approved a further investment of up to INR 16 Crore in HCG Rajkot Hospitals LLP, wholly owned subsidiary of the Company.

Detailed information in this regard in accordance with Regulation 30 read with SEBI Circulars is annexed herewith as Annexure.

The above information is also available on the website of the Company and can be accessed at: https://www.hcgoncology.com/

The meeting of the Board of Directors commenced at 11.30 a.m. and concluded at 6.50 p.m. IST.

Kindly take the intimation on record and acknowledge receipt of the same.

Thanking you,

For **HealthCare Global Enterprises Limited**

SUNU MANUEL ABEY

Digitally signed by SUNU MANUEL ABEY
Date: 2026.08.06 19:39:12 +05'30'

Sunu Manuel
Company Secretary & Compliance Officer
Encl: a/a.

ANNEXURE

Disclosures under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with Para 1.4 of Part A of Annexure 18 of the SEBI Master Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 issued on July 11, 2023, and last updated on January 30, 2026.

a) Name of the target entity, details in brief such as size, turnover etc;

HCG Rajkot Hospitals LLP ("HCG Rajkot") operates a cancer-specialty hospital in Rajkot, Gujarat, India, which has a licensed capacity of 147 beds, of which 134 beds are operational as on date. The turnover (revenue from operations) of HCG Rajkot for the financial year ended March 31, 2026, was INR 60.67 Crore.

b) Whether the acquisition would fall within related party transactions(s) and whether the promoter/promoter group/promoter group companies have any interest in the entity being acquired? If yes, nature of interest and details thereof and whether the same is done at "arm's length";

HCG Rajkot being a wholly owned subsidiary of the Company, qualifies as a related party under applicable regulations and accordingly, the transaction is a related party transaction and is being executed on an arm's length basis. Further, except to the extent of being wholly owned subsidiary, none of the promoter/promoter group/group companies have any interest in the proposed further acquisition.

c) Industry to which the entity being acquired belongs.

HCG Rajkot operates a cancer-specialty hospital in Rajkot, Gujarat, India.

d) Objects and impact of acquisition (including but not limited to, disclosure of reasons for acquisition of target entity, if its business is outside the main line of business of the listed entity);

The investment in HCG Rajkot is primarily for repayment of dues, working capital and for general corporate purposes.

e) Brief details of any governmental or regulatory approvals required for the acquisition.

The investment does not require approval from any governmental or regulatory authority.

f) **Indicative time period for completion of the acquisition.**

The investment will be completed on or before 30 September 2026.

g) **Nature of consideration – whether cash consideration or share swap and details of the same.**

The consideration for the further investment is in the form of cash.

h) **Cost of acquisition and/or the price at which the shares are acquired.**

The Company proposes to invest up to INR 16 Crore in HCG Rajkot.

i) **Percentage of shareholding/control acquired and/or number of shares acquired.**

The Company will continue to hold 100% of the capital in HCG Rajkot, post the investment.

j) **Brief background about the entity acquired in terms of products/line of business acquired, date of incorporation, history of last 3 years turnover, country in which the acquired entity has presence and any other significant information (in brief);**

HCG Rajkot was incorporated on September 22, 2017, and operates a cancer-specialty hospital in Rajkot, Gujarat, India. The turnover (revenue from operations) of HCG Rajkot for the financial years ended March 31, 2026, March 31, 2025, and March 21, 2024, was INR 60.67 Crores (approx.), INR 55.49 Crores (approx.) and INR 55.37 Crores (approx.), respectively.